Compare CHMG & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHMG | EOLS |
|---|---|---|
| Founded | 1833 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.1M | 284.3M |
| IPO Year | 1995 | 2018 |
| Metric | CHMG | EOLS |
|---|---|---|
| Price | $66.20 | $6.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $57.00 | $15.50 |
| AVG Volume (30 Days) | 10.0K | ★ 935.6K |
| Earning Date | 04-17-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ 1.91 | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | $37.32 | $13.27 |
| Revenue Next Year | $9.13 | $17.62 |
| P/E Ratio | $35.86 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $45.55 | $3.86 |
| 52 Week High | $70.83 | $10.62 |
| Indicator | CHMG | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 75.57 |
| Support Level | $50.67 | $5.88 |
| Resistance Level | $70.41 | $6.40 |
| Average True Range (ATR) | 2.52 | 0.36 |
| MACD | -0.24 | 0.12 |
| Stochastic Oscillator | 25.30 | 82.70 |
Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.